3036415-37-6
Chemical Structure
PSMA-trillium
Synonym(s): Felivotide mopaxetan
- CAS No.: 3036415-37-6
- Formula:C106H156IN17O34S
- Molecular Weight:2371.44
InChIKey: MTIIFJOITJQZRL-ONKCMSQHSA-N
SMILES: O=C([C@@H](NC(N[C@H](C(O)=O)CCCCNC(NC1=CC(C2=CN(N=N2)CCOCCOCCOCCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@H](C(O)=O)CCCCNC(CCCC3=CC=C(I)C=C3)=O)=O)=O)CCCCNC(NC4=CC=C(C=C4)CCOC5=CC(C(O)=O)=NC(CN6CCOCCOCCN(CC7=CC=CC(C(O)=O)=N7)CCOCCOCC6)=C5)=S)=O)=CC=C1)=O)=O)CCC(O)=O)O
Biological Activity: PSMA-trillium (Felivotide mopaxetan) is a PSMA-targeted molecule that contains a highly specific PSMA-binding motif, an albumin-binding domain optimized for tumor uptake and retention, and a Macropa chelator conjugated to the α-emitter 225Ac. PSMA-trillium binds to albumin to prolong plasma retention time and binds to PSMA via its specific motif. 225Ac-PSMA-Trillium exhibits dose-dependent inhibition of LNCaP tumor growth in mice. PSMA-trillium can be used in research related to prostate cancer and metastatic castration-resistant prostate cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PSMA-trillium | PSMA-trillium (Felivotide mopaxetan) is a PSMA-targeted molecule that contains a highly specific PSMA-binding motif, an albumin-binding domain optimized for tumor uptake and retention, and a Macropa chelator conjugated to the α-emitter 225Ac. PSMA-trillium binds to albumin to prolong plasma retention time and binds to PSMA via its specific motif. 225Ac-PSMA-Trillium exhibits dose-dependent inhibition of LNCaP tumor growth in mice. PSMA-trillium can be used in research related to prostate cancer and metastatic castration-resistant prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zitzmann-Kolbe S, et al. Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)[J]. Cancer Research, 2024, 84(6_Supplement): 6033-6033.
- [2]. Hagemann U B, et al. Comparative evaluation of 225Ac-PSMA-Trillium with other 225Ac-PSMA-SMOL assets in a preclinical prostate cancer xenograft model[J]. Cancer Research, 2026, 86(7_Supplement): 7202-7202.
